KRAS and colorectal carcinoma: KRAS mutant CRC patients with low intratumoral FTH expression had longer three- and five-year survival than those with high expression, but not in wild-type KRAS. This suggests that the effects of FTH on CRC may be affected by aberrant KRAS expression.